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870Although the usefulness of targeting nonculprit lesions
anticipated to be responsible for future cardiovascular
events is part of an ongoing investigation (PROSPECT II &
PROSPECT ABSORB—an Integrated Natural History Study
and Randomized Trial; NCT02171065), we agree with
Mahajan et al. that the true prevalence of ruptured or
eroded plaques according to detailed imaging modalities
such as OCT would be of paramount interest in patients
with stable coronary artery disease. However, they should
note that in theOCTAVIA (Optical CoherenceTomography
Assessment of Gender Diversity In Primary Angioplasty)
study, OCT imageswere obtained at baseline presentation
for STEMI, post-stent implantation, and at 9-month
follow-up in the culprit vessel only, as part of the pre-
speciﬁed study protocol. Therefore, no information can
be extrapolated from this study on the prevalence of
destabilizedplaques in nonculprit vessels. Differently, the
OCT technology available at the time of the study enabled
a pullback assessment of the culprit vessel starting from
approximately 2 cm distal to the target segment for a total
length of approximately 5.4 cmupstream. The prevalence
and fate of rupturedor erodedplaques in the culprit vessel
beyond the treated lesion along the studied segment will
be the objects of an upcoming separate OCTAVIA sub-
study, which is beyond the scope of the present reply.*Giulio Guagliumi, MD
Davide Capodanno, MD, PhD
Francesco Saia, MD, PhD
for the OCTAVIA Trial Investigators
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Using Unidirectional Left-
to-Right Interatrial Shunt
Initial Experience in Treating Symptomatic
Heart Failure With Preserved Ejection
Fraction With the W-Wave DeviceApproximately one-half of all heart failure (HF) pa-
tients have HF with preserved ejection fraction
(HFpEF); the incidence of which is expected to rise in
parallel with increasing life expectancy (1). Impor-
tantly, and unlike HF with reduced ejection fraction
(EF), no speciﬁc therapy has thus far proven efﬁca-
cious in pivotal clinical trials enrolling patients with
HFpEF. Most patients with decompensated HF pre-
sent with elevated left atrial (LA) pressure, and the
strict control of LA pressure via invasive monitoring
in these patients is associated with signiﬁcant im-
provements in New York Heart Association (NYHA)
functional class, and quality of life, and signiﬁcant
reductions in re-hospitalizations and mortality (2,3).
Reported experience with an open (non-valved)
interatrial shunt device (Interatrial Septal Device;
DC Devices Inc., Tewksbury, Massachusetts) have
demonstrated improvement in NYHA functional class
in HFpEF patients (4).
The V-Wave implantable shunt (V-Wave Ltd,
Or Akiva, Israel) consists of an ePTFE-encapsulated
hourglass shaped nitinol frame which is implanted at
the interatrial septum and contains 3 porcine pericar-
dial leaﬂets sutured within to ensure unidirectional
ﬂow from the left to the right atrium (Figure 1A). We
recently reported the initial successful clinical expe-
rience with the V-Wave device in a patient with sys-
tolic HF (5). The present case discusses the ﬁrst
experience with the V-Wave device in a patient with
HFpEF. A 64-year-old man with a history of coronary
artery disease, chronic atrial ﬁbrillation, and ischemic
cardiomyopathy with a left ventricular EF of 50% was
admitted to our center. Clinically, the patient had
HF symptoms of NYHA class III and orthopnea despite
high doses of diuretics (furosemide 240 mg/day in
divided doses). Right heart catheterization revealed
a mean pulmonary wedge pressure of 22 mm Hg, pul-
monary artery pressures of 68/21/(39) mm Hg, and a
mean right atrial pressure of 12mmHg. At baseline, the
6-min hall walk (6MHW) distance was 281 m, the
FIGURE 1 The V-Wave Device
(A) The V-Wave device consists of an hourglass-shaped nitinol frame with ePTFE encapsulation and 3 porcine pericardial leaﬂets sutured together with a Prolene suture.
The lumen size of the device is 5 mm at the level of the fossa. (B) Images obtained by transesophageal echocardiography showing the V-Wave device implanted at the
level of the fossa ovalis. (C) Normal ﬂow through the V-Wave device as evaluated by Doppler and color-Doppler during transesophageal echocardiography. (D) Three-
dimensional (3D) transesophageal echocardiography images of the V-Wave device immediately post-implantation showing adequate positioning at the fossa ovalis.
(E and F) 3D reconstruction images of the V-Wave device by computed tomography once implanted.
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871Kansas City Cardiomyopathy Questionnaire (KCCQ)
quality of life score was 38.3, and the NT-proBNP level
was 2,983 pg/ml. Following careful evaluation by the
heart failure team, the patient was considered a suit-
able candidate for the V-Wave device implantation.
The procedure was approved by Health Canada under
the Canadian Special Access program, and the patient
provided informed consent for the procedure. The V-
Wave shunt was implanted via the femoral venous
approach following transseptal puncture at the level of
the fossa ovalis (Figures 1B and 1C) using a 14-F sheath
which was advanced and positioned in the mid-LA.
The left side of the device was opened within the
mid-LA; retracted into the interatrial septum, where
the device was deployed; and ﬁnally, released by
further retracting the delivery catheter. The presence
of a left-to-right shunt through the device was
demonstrated by transesophageal echocardiography
(TEE) immediately following device implantation
(Figures 1B and 1C). Adequate device positioning was
veriﬁed by 3-dimensional TEE (Figure 1D) and com-
puted tomography (Figures 1E and 1F). The patient was
discharged 24 h post-procedure without complication.TEE at 3-month follow-up demonstrated interatrial
shunt patency, and the absence of thrombus. At the
6-month follow-up visit, NYHA class improved to
class II (1 class), the 6MHW distance improved to
617 m (þ336 m), the KCCQ score improved to 78.03
points (þ39.73 points), and the NT-proBNP level
decreased to 1,334 pg/ml (1,649 pg/ml) when com-
pared with baseline, and orthopnea was no longer
present. Echocardiography revealed no changes in
left and right ventricular systolic function or elevation
in pulmonary arterial pressures.
The present report demonstrates the feasibility
and promising preliminary results of creating a uni-
directional left-to-right shunt for treating HFpEF
symptoms. Extensive evaluation of this novel thera-
peutic approach in patients with symptomatic HFpEF
is warranted.
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